Expected Drop In COVID-19 Vaccine Sales Hits Beximco’s Bottom Line
Subsidiary Entities Collectively Profitable For First Time Following Synovia Acquisition
The absence of any income from distributing AstraZeneca’s COVID-19 vaccine led to Beximco’s pre-tax profit dropping by 13% in the first six months of its financial year ending in June 2023. However, profits after tax actually rose slightly when discounting last year’s COVID-19 vaccine impact.
